Traditional clinical biomarkers such as ALT, AST, and CK are not sensitive enough to detect subtle drug induced muscle injury and often do not correlate to results from immunohistopathology. The volume of sample required for these traditional assays is often larger than is feasible for rodent models in preclinical studies.
MSD offers multiplex panels of traditional and novel biomarkers for muscle injury that overcome these limitations. The panels include biomarkers such as FABP3, Myl3, and sTroponin I.